<DOC>
	<DOCNO>NCT00681538</DOCNO>
	<brief_summary>The purpose study determine whether Sativex® versus Placebo effective relief symptom spasticity subject multiple sclerosis , identify capacity respond Sativex .</brief_summary>
	<brief_title>A Study Safety Effectiveness Sativex® , Relief Symptoms Spasticity Subjects , From Phase B , With Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>This 19 week , multicentre study conduct two phase . Phase A preliminary , single-blind four week treatment period identify subject capacity respond Sativex ; eligible , consent subject enter seven day screen period prior return study centre begin four week single-blind course Sativex treatment . At end phase , subject ' response Sativex assess ; capacity respond ( i.e . least 20 % reduction mean 0-10 point numerical rating scale ( NRS ) spasticity score screen end four week Phase A treatment ) eligible entry Phase B respond take part study follow visit 14 day later . Phase B 12 week double-blind , randomise , placebo control , parallel group study visit 28 day interval final follow visit 14 day completion withdrawal . The level spasticity , spasm frequency sleep disruption collect day entire study via interactive voice response system ( IVRS ) . In addition , study medication dose data record via IVRS throughout Phases A B . Assessments secondary functional measure spasticity , safety tolerability , QOL ( quality life ) mood also gather throughout study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Willing able give write informed consent participation study . Male female , age 18 year . Subject able ( investigator 's opinion ) willing comply study requirement . Diagnosed disease subtype MS least six month duration . Spasticity due MS least three month duration , wholly relieve current antispasticity therapy , expect remain stable duration study . Subject fulfil least one two criterion . Subject must either : Currently establish regular dose antispasticity therapy Previously try fail , could tolerate suitable antispasticity therapy . Subject currently receive stable regimen ( least 30 day prior study entry ) medication may effect spasticity ; willing maintain duration study . If subject currently take diseasemodifying medication , must stable dose least three month prior screen visit ; dose must also remain stable duration study . Willing name notify primary care physician , consultant responsible authority participation study , applicable . Any concomitant disease disorder spasticitylike symptom may influence subject 's level spasticity . Subject 's medical history suggest relapse/remission likely occur study ( next 19 week ) , opinion investigator , expect influence subject 's spasticity . Currently receive prohibit medication unwilling stop state period prior screen visit duration study . Any known suspected history : schizophrenia psychotic illness ; diagnose dependence disorder ; poorly control epilepsy recurrent seizure ; hypersensitivity cannabinoids . Significant cardiac , renal hepatic disease . Female subject child bear potential male subject whose partner child bear potential , unless willing ensure partner use effective contraception study three month thereafter . Female subject pregnant , lactate plan pregnancy course study three month thereafter . Subjects receive IMP within 12 week Visit 1 . Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Following physical examination , subject abnormality , opinion investigator , would prevent safely participate study . Unwilling abstain donation blood study . Travel outside country residence plan study . Subjects previously randomise study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>